Literature DB >> 25780323

Influence of Access, Anticoagulant, and Bleeding Definition on Outcomes of Primary Percutaneous Coronary Intervention: Early Experience of an US Academic Center.

M K Bheemarasetti1, S Shawar1, S Chithri1, W I Khalife1, U M Rangasetty1, K Fujise1, S A Gilani1.   

Abstract

Background We aimed to carry out comparison of different bleeding avoidance strategies in doing primary percutaneous coronary intervention (PPCI) using either radial or femoral as access of choice and either bivalirudin or unfractionated heparin as anticoagulant of choice. In this analysis, we analyzed the influence of major bleeding definition on bleeding outcomes as well. Methods We did a retrospective analysis of 139 patients with ST-segment elevation myocardial infarction (STEMI) who had PPCI in our academic center from January 2010 till October 2013. The primary outcome at 30 days was a composite of death from any cause or stent thrombosis or non-coronary artery bypass grafting (CABG) related major bleeding (CathPCI Registry definition) and secondary outcomes were individual components of primary outcome and the hospital length of stay. Results There was no significant difference among different access/anticoagulant combinations with regards to primary outcome (22% in radial/bivalirudin vs. 5% in radial/heparin vs. 17% in femoral/bivalirudin vs. 28% in femoral/heparin group; p = 0.2) as well as its individual components except the hospital length of stay (2.56 vs. 3 vs. 3.97 vs. 4.4 days each; p < 0.0001). The overall rate of major bleeding was 11.5%. When we use HORIZON-AMI bleeding definition, it went up to 25 % due to one particular component (p < 0.004). Conclusions This single center observational study doing PPCI did not show any superiority of one bleeding avoidance strategy over others with regard to primary outcome and its individual components except the hospital length of stay. It also shows the importance of bleeding definition on bleeding outcomes.

Entities:  

Keywords:  bivalirudin; bleeding definition; radial access

Year:  2015        PMID: 25780323      PMCID: PMC4347827          DOI: 10.1055/s-0034-1394158

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  18 in total

Review 1.  Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice.

Authors:  Brendan J Doyle; Charanjit S Rihal; Dennis A Gastineau; David R Holmes
Journal:  J Am Coll Cardiol       Date:  2009-06-02       Impact factor: 24.094

2.  Bivalirudin started during emergency transport for primary PCI.

Authors:  Philippe Gabriel Steg; Arnoud van 't Hof; Christian W Hamm; Peter Clemmensen; Frédéric Lapostolle; Pierre Coste; Jurrien Ten Berg; Pierre Van Grunsven; Gerrit Jan Eggink; Lutz Nibbe; Uwe Zeymer; Marco Campo dell' Orto; Holger Nef; Jacob Steinmetz; Louis Soulat; Kurt Huber; Efthymios N Deliargyris; Debra Bernstein; Diana Schuette; Jayne Prats; Tim Clayton; Stuart Pocock; Martial Hamon; Patrick Goldstein
Journal:  N Engl J Med       Date:  2013-10-30       Impact factor: 91.245

3.  Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.

Authors:  Roxana Mehran; Sunil V Rao; Deepak L Bhatt; C Michael Gibson; Adriano Caixeta; John Eikelboom; Sanjay Kaul; Stephen D Wiviott; Venu Menon; Eugenia Nikolsky; Victor Serebruany; Marco Valgimigli; Pascal Vranckx; David Taggart; Joseph F Sabik; Donald E Cutlip; Mitchell W Krucoff; E Magnus Ohman; Philippe Gabriel Steg; Harvey White
Journal:  Circulation       Date:  2011-06-14       Impact factor: 29.690

4.  Impact of femoral vascular closure devices and antithrombotic therapy on access site bleeding in acute coronary syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.

Authors:  Timothy A Sanborn; Ramin Ebrahimi; Steven V Manoukian; Brent T McLaurin; David A Cox; Frederick Feit; Martial Hamon; Roxana Mehran; Gregg W Stone
Journal:  Circ Cardiovasc Interv       Date:  2010-01-26       Impact factor: 6.546

5.  Bivalirudin or heparin in primary angioplasty performed through the transradial approach: results from a multicentre registry.

Authors:  Alessandro Sciahbasi; Stefano Rigattieri; Bernardo Cortese; Flavia Belloni; Carmelo Russo; Alessandro Ferraironi; Maurizio Tespili; Chiara Angeletti; Roberto Ricci; Francesco Bondanini; Francesco Rocco Pugliese
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2014-01-07

6.  Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.

Authors:  Sanjit S Jolly; Salim Yusuf; John Cairns; Kari Niemelä; Denis Xavier; Petr Widimsky; Andrzej Budaj; Matti Niemelä; Vicent Valentin; Basil S Lewis; Alvaro Avezum; Philippe Gabriel Steg; Sunil V Rao; Peggy Gao; Rizwan Afzal; Campbell D Joyner; Susan Chrolavicius; Shamir R Mehta
Journal:  Lancet       Date:  2011-04-04       Impact factor: 79.321

Review 7.  Radial versus femoral access for primary percutaneous interventions in ST-segment elevation myocardial infarction patients: a meta-analysis of randomized controlled trials.

Authors:  Wassef Karrowni; Ankur Vyas; Bria Giacomino; Marin Schweizer; Amy Blevins; Saket Girotra; Phillip A Horwitz
Journal:  JACC Cardiovasc Interv       Date:  2013-08       Impact factor: 11.195

8.  Observations on blood viscosity changes after acute myocardial infarction.

Authors:  K M Jan; S Chien; J T Bigger
Journal:  Circulation       Date:  1975-06       Impact factor: 29.690

9.  Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study.

Authors:  Enrico Romagnoli; Giuseppe Biondi-Zoccai; Alessandro Sciahbasi; Luigi Politi; Stefano Rigattieri; Gianluca Pendenza; Francesco Summaria; Roberto Patrizi; Ambra Borghi; Cristian Di Russo; Claudio Moretti; Pierfrancesco Agostoni; Paolo Loschiavo; Ernesto Lioy; Imad Sheiban; Giuseppe Sangiorgi
Journal:  J Am Coll Cardiol       Date:  2012-08-01       Impact factor: 24.094

10.  Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.

Authors:  A K Rao; C Pratt; A Berke; A Jaffe; I Ockene; T L Schreiber; W R Bell; G Knatterud; T L Robertson; M L Terrin
Journal:  J Am Coll Cardiol       Date:  1988-01       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.